Skip to main contentAI and Advanced
/
WOCKPHARMA · NSEBSE SENSEX74,294.96-0.03%BSE |
NIFTY 5023,346.4+0.33%NSE |
NIFTY BANK56,358.7+0.54%NSE |
NIFTY IT28,854.55-1.03%NSE |
NIFTY AUTO27,129-0.11%NSE |
NIFTY FMCG45,466.8-0.23%NSE |
NIFTY PHARMA26,710.1+0.49%NSE |
NIFTY 50022,840.55+0.82%NSE |
WO
NSE · Equity shares · Biotechnology & Drugs13.80 · 0.67%
Wockhardt WOCKPHARMA
NSE:INR 2,086.1
BSE:INR 2,082.45
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for WOCKPHARMA
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 2,072.3
Day rangeINR 2,047.3 — INR 2,109.3
52-week rangeINR 1,086.7 — INR 2,422.3
Volume5.57 L
Market cap32,090.9
P/E89.53
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)3,373
Net Income (INR Cr)213
Rev Growth (5 Year %)4.49
P/E Ratio89.53
Book Value126.71
EPS14.64
Price/BV16.46Computed
Research path: Interpret Wockhardt's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
WOCKPHARMAWockhardt1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 8,615 | 8,135 | 7,649 |
| Accumulated Depreciation Total | -2,862 | -2,596 | -2,376 |
| Other Liabilities Total | 119 | 95 | 100 |
| Accrued Expenses | 57 | 28 | 41 |
| Long Term Debt | 1,518 | 1,211 | 891 |
| Common Stock Total | 81 | 81 | 77 |
| Other Equity Total | 808 | 500 | 435 |
| Other Current Assets Total | 124 | 183 | 135 |
| Total Assets | 8,615 | 8,135 | 7,649 |
| Current Portof LT Debt/Capital Leases | 239 | 219 | 463 |
| Additional Paid-In Capital | 2,240 | 2,239 | 1,261 |
| Cash | 217 | 112 | 505 |
| Total Equity | 4,940 | 4,353 | 3,359 |
| Retained Earnings(Accumulated Deficit) | 1,811 | 1,533 | 1,586 |
| Total Common Shares Outstanding | 16.25 | 16.25 | 15.34 |
| Property/Plant/Equipment Total-Gross | 5,151 | 4,827 | 4,685 |
| Tangible Book Valueper Share Common Eq | 126.71 | 111.7 | 69.43 |
| Goodwill Net | 1,028 | 977 | 953 |
| Total Liabilities | 3,675 | 3,782 | 4,290 |
| Total Debt | 2,233 | 2,021 | 2,356 |
| Short Term Investments | 412 | 422 | Not available |
| Cashand Short Term Investments | 629 | 534 | 505 |
| Total Receivables Net | 1,007 | 1,029 | 857 |
| Notes Payable/Short Term Debt | 438 | 496 | 832 |
| Deferred Income Tax | 37 | 35 | 35 |
| Accounts Receivable-Trade Net | 588 | 661 | 618 |
| Property/Plant/Equipment Total-Net | 2,289 | 2,231 | 2,309 |
| Minority Interest | 341 | 304 | 303 |
| Total Current Liabilities | 1,622 | 2,042 | 2,791 |
| Total Inventory | 937 | 823 | 687 |
| Accounts Payable | 563 | 592 | 766 |
| Other Currentliabilities Total | 325 | 707 | 689 |
| Total Long Term Debt | 1,556 | 1,306 | 1,061 |
| Intangibles Net | 1,853 | 1,561 | 1,341 |
| Other Long Term Assets Total | 572 | 623 | 658 |
| Note Receivable-Long Term | 176 | 174 | 204 |
| Total Current Assets | 2,697 | 2,569 | 2,184 |
| Capital Lease Obligations | 38 | 95 | 170 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %-3.53
Margins
Operating Margin 12m9.43
Operating Margin 5y Avg-0.67
Net Profit Margin 12m5.9
Net Profit Margin 5y-8.17
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio9.51
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk48.65
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 49.08%
- FII
- 7.22%
- MF
- 6.79%
- Other
- 36.91%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Top Gainers & Losers on May 5: Wockhardt, Tata Tech, Gabriel India, Dabur, Adani Green Energy among top gainersMarket news · 5 May 2026, 3:36 pm
Indian markets showed volatility on May 5 amid escalating US-Iran tensions. The Nifty 50 ended up 0.36%, while the Sensex declined 0.33%. Notable gainers included CreditAccess Grameen and Wockhardt, though profit-taking led to losses in several other stocks.
Wockhardt shares surge over 12% to 9-month high as company swings to profit in Q4Market news · 5 May 2026, 2:51 pm
Wockhardt's shares surged 12.55% to ₹ 1,604 following a profitable Q4FY26 with a net profit of ₹ 164 crore. Strong revenue growth from biotech and emerging markets fueled performance, with full-year revenue rising to ₹ 3,373 crore and EBITDA increasing by 51%.
Buy or sell: Ganesh Dongre recommends three stocks to buy on Monday — 19 January 2026Market news · 18 Jan 2026, 12:18 pm
Buy or sell: Ganesh Dongre recommends three stocks to buy on Monday — Wockhardt, LT, and HDFC Bank.
Top Gainers & Losers on Dec 05: Patanjali Foods, RBL Bank, Wockhardt, MCX, Suzlon Energy among top gainersMarket news · 5 Dec 2025, 3:40 pm
Following a repo rate cut by the RBI, the Indian stock market saw renewed optimism, with Nifty 50 and Sensex gaining. Key sectors like PSU Banks and IT led the rally, despite mixed performance in broader markets.
Wockhardt share price jumps 27% in 2 days after US FDA accepts new drug application for breakthrough antibiotic ZaynichMarket news · 2 Dec 2025, 10:47 am
Wockhardt's share price surged 6.5% following FDA acceptance of its New Drug Application for Zaynich, marking a significant milestone for Indian pharma. The two-day rally reached nearly 27%, reflecting renewed investor interest and highlighting India's potential in global antibiotic innovation.
Top Gainers & Losers on Dec 01: Wockhardt, JM Financial, TVS Motor, Hindustan Copper, Paytm among top gainersMarket news · 1 Dec 2025, 3:40 pm
Indian stocks declined on December 01 after reaching highs, influenced by a record low rupee against the dollar and foreign investor selling. The Nifty 50 fell 150 points, closing at 26,175, while the Sensex dropped 531 points to 85,625.
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsInter-alia, to consider 1. Raising of funds by issue of Equity Shares, American Depository Receipts , Foreign Currency Convertible Bonds or any combination thereof or any other method.
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
Rusaka Markets Community
Discussion and sentiment for Wockhardt
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- WOCKPHARMA
- BSE Code
- 532300
Questions
Stock FAQ
What is the symbol and ISIN of Wockhardt?
Wockhardt has the symbol WOCKPHARMA and ISIN - INE049B01025.
What is the current price of Wockhardt?
Wockhardt is currently trading at INR 2,086.10.
What are the year high and year low of Wockhardt?
Wockhardt has a year high of INR 2,422.30 and a year low of INR 1,086.70.
What is the market capitalization of Wockhardt?
Wockhardt has a market capitalization of INR 32,090.90 crore.
What is the P/E ratio of Wockhardt?
Wockhardt has a P/E ratio of 89.53.
What is the dividend yield of Wockhardt?
Wockhardt has a dividend yield of 0.00%.
How is the financial performance of Wockhardt based on revenue, net income, and EPS?
Wockhardt has revenue of INR 3,373.00 crore, net income of INR 213.00 crore, and EPS of INR 16.35.
What is the book value of Wockhardt?
Wockhardt has a book value of INR 126.71.
What is the debt-to-equity ratio of Wockhardt?
Wockhardt has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Wockhardt?
Wockhardt has a price-to-book ratio of 16.46 and a price-to-sales ratio of 9.51.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.